ATE303158T1 - Verwendung von beta-interferon zur behandlung der restenose - Google Patents

Verwendung von beta-interferon zur behandlung der restenose

Info

Publication number
ATE303158T1
ATE303158T1 AT96940704T AT96940704T ATE303158T1 AT E303158 T1 ATE303158 T1 AT E303158T1 AT 96940704 T AT96940704 T AT 96940704T AT 96940704 T AT96940704 T AT 96940704T AT E303158 T1 ATE303158 T1 AT E303158T1
Authority
AT
Austria
Prior art keywords
beta
interferon
treat restenosis
treat
restenosis
Prior art date
Application number
AT96940704T
Other languages
English (en)
Inventor
Anthony Johns
Robert J Mintzer
Original Assignee
Berlex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Lab filed Critical Berlex Lab
Application granted granted Critical
Publication of ATE303158T1 publication Critical patent/ATE303158T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT96940704T 1995-11-30 1996-11-28 Verwendung von beta-interferon zur behandlung der restenose ATE303158T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/565,701 US5681558A (en) 1995-11-30 1995-11-30 Method of using beta-interferons to treat restenosis
PCT/IB1996/001468 WO1997019697A1 (en) 1995-11-30 1996-11-28 Method of using beta-interferons to treat restenosis

Publications (1)

Publication Number Publication Date
ATE303158T1 true ATE303158T1 (de) 2005-09-15

Family

ID=24259751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940704T ATE303158T1 (de) 1995-11-30 1996-11-28 Verwendung von beta-interferon zur behandlung der restenose

Country Status (11)

Country Link
US (1) US5681558A (de)
EP (1) EP0869813B1 (de)
JP (2) JP4116075B2 (de)
AT (1) ATE303158T1 (de)
AU (1) AU712960B2 (de)
CA (1) CA2238871C (de)
DE (1) DE69635131T2 (de)
DK (1) DK0869813T3 (de)
ES (1) ES2247607T3 (de)
WO (1) WO1997019697A1 (de)
ZA (1) ZA9610073B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
US7018371B2 (en) * 2001-05-07 2006-03-28 Xoft, Inc. Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia
US6537195B2 (en) 2001-05-07 2003-03-25 Xoft, Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
SE462364B (sv) * 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
JPH04116075A (ja) * 1990-09-03 1992-04-16 Hitachi Building Syst Eng & Service Co Ltd エレベータの乗り場報知装置
HU220969B1 (hu) * 1993-01-07 2002-07-29 Thomas Jefferson University A C-MYC-re specifikus antiszensz oligonukleotid alkalmazása simaizomsejtek proliferációjának szabályozásában
US6780406B1 (en) * 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
EP0797998A4 (de) * 1995-11-17 2003-01-15 Toray Industries Schutz für endothelzellen

Also Published As

Publication number Publication date
DE69635131D1 (de) 2005-10-06
DK0869813T3 (da) 2006-01-02
EP0869813B1 (de) 2005-08-31
JP4116075B2 (ja) 2008-07-09
ZA9610073B (en) 1997-06-18
CA2238871A1 (en) 1997-06-05
ES2247607T3 (es) 2006-03-01
AU1070397A (en) 1997-06-19
EP0869813A1 (de) 1998-10-14
WO1997019697A1 (en) 1997-06-05
US5681558A (en) 1997-10-28
EP0869813A4 (de) 2003-02-05
JP2000501093A (ja) 2000-02-02
CA2238871C (en) 2006-08-15
DE69635131T2 (de) 2006-07-06
JP2008031179A (ja) 2008-02-14
AU712960B2 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
ATE271041T1 (de) Analoga von duocarmycin and cc-1065
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69004081T2 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
DE69212620T2 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
AP9100310A0 (en) Tnf inhibitors
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
ATE303158T1 (de) Verwendung von beta-interferon zur behandlung der restenose
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE68923219D1 (de) Behandlung von Abfällen.
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
ES2070134T3 (es) Inhibidores de lisil oxidasa.
DE68907569T2 (de) Mittel zur Behandlung oder Vorbeugung von Aids.
ATE238795T1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
DE69806062T2 (de) Kombinationstherapie zur behandlung von aids
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0869813

Country of ref document: EP

REN Ceased due to non-payment of the annual fee